Annual fundraiser supports the foundation's efforts to raise awareness and improve quality of life for adults and children ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...

Stress isnt the cause of IBD but minimising it may be your secret weapon for living better with the condition Read ahead to ...

When Phyllis Burk was diagnosed with Crohn’s disease nearly 50 years ago, it wasn’t as simple as looking up information ...

HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at ...

Healwell AI shares advanced after the company said it demonstrated real-world examples of using artificial intelligence to generate high-quality data for a major pharmaceutical company. Shares traded ...

People with inflammatory bowel disease, like ulcerative colitis, are 2 to 3 times more likely to develop blood clots than ...

In a randomized trial, 1 day of octreotide infusion combined with endoscopic therapy proved noninferior to 5 days for acute ...

First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapies Topline safety, PK, and PD data anticipated in Q1 2026 Advances ongoing ...

In the realm of gastroenterology, inflammatory bowel disease (IBD), encompassing Crohn’s disease (CD) and ulcerative colitis (UC), presents a significant therapeutic challenge due to its chronic ...

The FDA updated the indication of the JAK inhibitor upadacitinib (Rinvoq) in inflammatory bowel disease (IBD) to account for cases where a patient may not be appropriate for a TNF blocker, drugmaker ...